scholarly journals A Case of Intravascular Diffuse Large B-Cell Lymphoma Initially Suspected as Interstitial Pneumonia Associated With Systemic Scleroderma

2021 ◽  
Vol 9 ◽  
pp. 232470962199922
Author(s):  
Tomoyo Oguri ◽  
Shinji Sasada ◽  
Yuki Aramaki-Sumii ◽  
Yumi Tsuchiya ◽  
Kota Ishioka ◽  
...  
Keyword(s):  
B Cell ◽  
Interstitial Pneumonia ◽  
Cell Lymphoma ◽  
Ground Glass Opacity ◽  
B Cell Lymphoma ◽  
Systemic Scleroderma ◽  
Ground Glass ◽  
Serum Lactate Dehydrogenase ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Intravascular large B-cell lymphoma (IVLBCL) is a rare form of diffuse LBCL. The patient was a 71-year-old female admitted to our hospital with hypoxia. On admission, chest computed tomography revealed a ground-glass opacity. Interstitial pneumonia associated with systemic scleroderma was suspected because of positive anti-centromere antibody. Thereafter, steroid pulse therapy and plasma exchange were performed. Although ground-glass opacity improved, bilateral pleural effusion appeared, so we performed a random skin biopsy because of her elevated serum lactate dehydrogenase and soluble interleukin-2 receptor levels. The patient was diagnosed with IVLBCL with symptoms improving after 6 cycles of rituximab plus chemotherapy treatment.

Prognostic implications of caspase-3 expression in patients with diffuse large B-cell lymphoma (DLBCL)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17500-17500 ◽  
Author(s):  
W. H. Elsawy ◽  
M. Abdel Kader ◽  
A. Elfar ◽  
A. Gharib ◽  
S. Eltrhony ◽  
...  
Keyword(s):  
B Cell ◽  
Tumor Cells ◽  
Poor Prognosis ◽  
Caspase 3 ◽  
Cell Lymphoma ◽  
International Prognostic Index ◽  
B Cell Lymphoma ◽  
Serum Lactate Dehydrogenase ◽  
Large B Cell Lymphoma ◽  
Large B Cell

17500 Background: Caspase-3 activation is an essential step in programmed cell death (apoptosis) and cytotoxic drug-induced apoptosis is mediated by caspase-2 and caspase-3. The following study was designed to evaluate the correlation between Caspase-3 and the clinical outcome in patients with diffuse large B-cell lymphoma. Methods: Caspase-3 was determined by both immunohistochemistry and by quantitative reverse-transcription PCR in 49 previously untreated patients with diffuse large B-cell lymphoma. Results: Caspase-3 was positive in 69.4% of the patients by immunostaining and Tumor cells displayed a diffuse cytosolic expression in 51% of patients. The median value of Caspase-3mRNA within the group by quantitative PCR was 1. Caspase-3mRNA level was μ1 in 28 patients and <1 in 21 patients. Caspase-3 expression was associated with higher tumor stage (P = 0.03), elevated serum lactate dehydrogenase levels (P = 0.02), and the International Prognostic Index (P = 0.0001). Patients with Caspase-3-positive immunostaining had a significantly higher complete response rate to chemotherapy and a longer overall survival than Caspase-3-negative patients. Also, patients with tumor cells expressing diffuse cytosolic immunostaining for caspase-3 had a poor prognosis when compared with those expressing a punctate staining (P > 0.0004 log-rank). A low caspase-3 mRNA expression by quantitative RT-PCR was also associated with a poor prognosis, although this was not statistically significant. In addition, patients with a high TUNEL positivity had a low survival probability (P > 0.02). Conclusions: Our results suggest that Caspase-3 activation or its lack may be a powerful independent predictor of response and survival in previously untreated diffuse large B-cell lymphomas. No significant financial relationships to disclose.

Primary Mediastinal Large B-Cell Lymphoma With Sclerosis in Pediatric and Adolescent Patients: Treatment and Results From Three Therapeutic Studies of the Berlin-Frankfurt-Münster Group

2003 ◽  
Vol 21 (9) ◽  
pp. 1782-1789 ◽  
Author(s):  
K. Seidemann ◽  
M. Tiemann ◽  
I. Lauterbach ◽  
G. Mann ◽  
I. Simonitsch ◽  
...  
Keyword(s):  
Cell Therapy ◽  
B Cell ◽  
Pediatric Patients ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Serum Lactate Dehydrogenase ◽  
High Dose ◽  
Large B Cell Lymphoma ◽  
Increased Risk ◽  
Large B Cell

Purpose: Primary mediastinal large B-cell lymphoma with sclerosis (PMLBL) is a rare entity of non-Hodgkin’s lymphoma (NHL) arising from thymic mature B cells. Optimal treatment strategies remain to be established, especially in pediatric patients. Patients and Methods: This study analyzes clinical characteristics and treatment outcome of 30 pediatric patients with PMLBL, diagnosed in multicenter therapy NHL–Berlin-Frankfurt-Münster Group (BFM) trials. Treatment was stratified by stage and serum lactate dehydrogenase (LDH) and consisted of four to six 5-day courses of chemotherapy using steroids, oxazaphosphorine alkylating agents, methotrexate, cytarabine, etoposide, and doxorubicin. Radiation was not part of the protocol. Results: From April 1986 to August 1999, 1,650 patients with newly diagnosed NHL were enrolled in the NHL-BFM trials; 30 patients (1.8%) had PMLBL. Median age was 14.3 years (range, 1.4 to 16.7 years); 15 patients were male and 15 patients were female. With a median observation time of 5 years (range, 1 to 12 years), probability of event-free survival (pEFS) at 5 years was 0.70 (SE, 0.08). Two patients erroneously diagnosed as T-cell NHL received non–B-cell therapy and died from progress of disease. Events in 28 patients receiving B-cell therapy included early progress during therapy (n = 1) and relapse (n = 6). Residual mediastinal masses were present in 23 patients after two courses of therapy and in 15 patients after the end of therapy. LDH ≥ 500 U/L was associated with increased risk of failure in multivariate analysis. Conclusion: PMLBL mainly is found in adolescents. Dose-intense chemotherapy including high-dose methotrexate yields a pEFS at 5 years of 0.70 (SE, 0.08). LDH is of prognostic value in pediatric patients with PMLBL.

Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin

2005 ◽  
Vol 23 (12) ◽  
pp. 2797-2804 ◽  
Author(s):  
Armando López-Guillermo ◽  
Luis Colomo ◽  
Mónica Jiménez ◽  
Francesc Bosch ◽  
Neus Villamor ◽  
...  
Keyword(s):  
Lymph Node ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Primary Site ◽  
Proliferation Index ◽  
Serum Lactate Dehydrogenase ◽  
Early Stage Disease ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Purpose To study the main clinicobiologic features, response, and outcome of patients with diffuse large B-cell lymphoma (DLBCL) according to the primary site, lymph node, or different extranodal organs of the disease. Patients and Methods We included 382 patients consecutively diagnosed with DLBCL in a single institution during a 13-year period. Morphology, immunophenotyping, proliferation index, differentiation profile, bcl-2/JH rearrangement, and clinical characteristics were analyzed according to the primary site of the lymphoma. Results Sites of the disease were: lymph node, 222 cases (58%); Waldeyer's ring (WR), 42 (11%); and extranodal sites, 118 (31%), including GI tract in 45 cases. Primary extranodal cases, particularly GI, showed a bcl-6 expression more frequently than nodal cases. Patients with primary WR or GI lymphomas presented with early-stage disease, no marrow infiltration, normal serum lactate dehydrogenase, and low- to low/intermediate-risk international prognostic index (IPI) more frequently than the remainder. Complete response (CR) rate was 63%, with WR and GI lymphomas having a higher CR rate (85% and 80%, respectively) than the other groups. In the whole series, 5-year overall survival (OS) was 52%. Patients with WR or GI lymphomas showed better OS (5-year OS: 77% and 68%, respectively) than patients with nodal or other extranodal sites. In the multivariate analysis, IPI, bulky disease, and β2-microglobulin were the main variables to predict OS; no nodal or extranodal site maintained their prognostic value. Conclusion In the present series, the primary site of disease was associated with particular clinicopathologic features and outcome, though the latter largely depended on other factors.

scholarly journals Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Wei Qin ◽  
Di Fu ◽  
Qing Shi ◽  
Lei Dong ◽  
Hongmei Yi ◽  
...  
Keyword(s):  
B Cell ◽  
Signaling Pathway ◽  
Cell Lymphoma ◽  
International Prognostic Index ◽  
B Cell Lymphoma ◽  
Serum Lactate Dehydrogenase ◽  
Molecular Characteristics ◽  
Molecular Heterogeneity ◽  
Large B Cell Lymphoma ◽  
Large B Cell

The clinical and molecular characteristics of localized diffuse large B-cell lymphoma (DLBCL) with single nodal (SN) or single extranodal (SE) involvement remain largely elusive in the rituximab era. The clinical data of 181 patients from a retrospective cohort and 108 patients from a phase 3 randomized trial NHL-001 (NCT01852435) were reviewed. Meanwhile, genetic aberrations, gene expression pattern, and tumor immunophenotype profile were revealed by DNA and RNA sequencing of 116 and 53 patients, respectively. SE patients showed similar clinicopathological features as SN patients, except for an increased percentage of low-intermediate risk in the National Comprehensive Cancer Network–International Prognostic Index. According to the molecular features, increased MPEG1 mutations were observed in SN patients, while SE patients were associated with upregulation of TGF-β signaling pathway and downregulation of T-cell receptor signaling pathway. SE patients also presented immunosuppressive status with lower activity of killing of cancer cells and recruiting dendritic cells. Extranodal involvement had no influence on progression-free survival (PFS) or overall survival (OS) in localized DLBCL. Serum lactate dehydrogenase &gt;3 upper limit of normal was an independent adverse prognostic factor for OS, and ATM mutations were related to inferior PFS. Although the overall prognosis is satisfactory, specific clinical, genetic, and microenvironmental factors should be considered for future personalized treatment in localized DLBCL.

Low Absolute Lymphocyte Count and Addition of Rituximab Confer High Risk for Interstitial Pneumonia In Patients with Diffuse Large B Cell Lymphoma

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1805-1805
Author(s):  
Yuan-Bin Yu ◽  
Yu-Chung Huang ◽  
Chia-Jen Liu ◽  
Jih-tung Pai ◽  
Hsueh-Ju Lu ◽  
...  
Keyword(s):  
Risk Factors ◽  
B Cell ◽  
Interstitial Pneumonia ◽  
Lymphocyte Count ◽  
Conflicts Of Interest ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Absolute Lymphocyte Count ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract Abstract 1805 Purpose: Several studies reported pulmonary toxicities in patients with diffuse large B cell lymphoma (DLBCL) receiving rituximab and chemotherapy. This retrospective study aimed to determine the risk factors and clinical characteristics of interstitial pneumonia in patients with DLBCL. Methods: From January 2000 to May 2009, 529 consecutive patients with DLBCL receiving first-line COP- or CHOP-based chemotherapy with or without rituximab in Taipei Veterans General Hospital were enrolled. Interstitial pneumonia (IP) was defined as diffuse pulmonary interstitial infiltrates found on computed tomography scan as well as respiratory symptoms. Patient characteristics and outcome parameters were retrieved via medical chart review. Results: IP was observed in 26 patients (4.9%) and 6 of them were confirmed asPneumocystis jirovecii pneumonia. The median number of chemotherapy course to IP was 4 cycles (range, 1–7). By multivariate logistic regression, absolute lymphocyte count (ALC) less than 1×109/L before treatment (odds ratio [OR] 2.75, 95% confidence interval [CI] 1.23–6.19) and addition of rituximab to chemotherapy (OR 4.56, 95% CI 1.68–12.39) were identified as independent risk factors for IP. In the rituximab-treated patients, low ALC at baseline further increased the risk for IP. Conclusions: Incidence of IP is increased in patients with DLBCL receiving rituximab-containing chemotherapy. Specific subgroup with lymphopenia at diagnosis should receive more attention in detecting this pulmonary complication. Disclosures: No relevant conflicts of interest to declare.

Diffuse Large B-cell Lymphoma of the Lung in a Patient With Nonspecific Interstitial Pneumonia

2019 ◽  
Vol 15 (6) ◽  
pp. e151-e152
Author(s):  
Luis Gorospe Sarasúa ◽  
Paola Arrieta ◽  
Anabelle Chinea-Rodríguez ◽  
Carlos de la Puente-Bujidos
Keyword(s):  
B Cell ◽  
Interstitial Pneumonia ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Nonspecific Interstitial Pneumonia ◽  
Large B Cell

scholarly journals A Case of Diffuse Large B-cell Lymphoma of the Lung Demonstrating Diffuse Ground-glass Shadows

2011 ◽  
Vol 17 (6) ◽  
pp. 591-594 ◽  
Author(s):  
Saiko Ogata-Suetsugu ◽  
Takashige Maeyama ◽  
Masafumi Takeshita ◽  
Naoki Hamada ◽  
Koichi Takayama ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Ground Glass ◽  
Large B Cell Lymphoma ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document